Adam B. Polis

2.8k total citations · 1 hit paper
48 papers, 1.8k citations indexed

About

Adam B. Polis is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Pharmacology. According to data from OpenAlex, Adam B. Polis has authored 48 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Surgery, 17 papers in Endocrinology, Diabetes and Metabolism and 11 papers in Pharmacology. Recurrent topics in Adam B. Polis's work include Lipoproteins and Cardiovascular Health (22 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (14 papers) and Cancer, Lipids, and Metabolism (11 papers). Adam B. Polis is often cited by papers focused on Lipoproteins and Cardiovascular Health (22 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (14 papers) and Cancer, Lipids, and Metabolism (11 papers). Adam B. Polis collaborates with scholars based in United States, Italy and Japan. Adam B. Polis's co-authors include Gregory P. Geba, Joanne E. Tomassini, Arthur L. Weaver, Mary Dixon, Gary A. Puckrein, Brenda D. Jamerson, Ola Akinboboye, Laurence O. Watkins, Ileana L. Piña and Jeanne M. Regnante and has published in prestigious journals such as JAMA, Annals of Internal Medicine and Journal of the American College of Cardiology.

In The Last Decade

Adam B. Polis

48 papers receiving 1.7k citations

Hit Papers

Increasing Diversity in Clinical Trials: Overcoming Criti... 2018 2026 2020 2023 2018 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Increasing Diversity in Clinical Trials: Overcoming Critical Barriers
    2018 465 citations Adam B. Polis et al. profile →

Peers

Adam B. Polis
Daniel R. Morales United Kingdom
Rita Schinnar United States
Brian P. Smith United States
Julie Parkes United Kingdom
Dena Rosen Ramey United States
John Reckless United Kingdom
Frank Andersohn Germany
W W Yeo United Kingdom
Concetta Rafaniello Italy
R. Lassalle France
Daniel R. Morales United Kingdom
Adam B. Polis
Citations per year, relative to Adam B. Polis Adam B. Polis (= 1×) peers Daniel R. Morales

Countries citing papers authored by Adam B. Polis

Since Specialization
Citations

This map shows the geographic impact of Adam B. Polis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam B. Polis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam B. Polis more than expected).

Fields of papers citing papers by Adam B. Polis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam B. Polis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam B. Polis. The network helps show where Adam B. Polis may publish in the future.

Co-authorship network of co-authors of Adam B. Polis

This figure shows the co-authorship network connecting the top 25 collaborators of Adam B. Polis. A scholar is included among the top collaborators of Adam B. Polis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam B. Polis. Adam B. Polis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tóth, Peter P., Harold Bays, W. Virgil Brown, et al.. (2019). Comparing remnant lipoprotein cholesterol measurement methods to evaluate efficacy of ezetimibe/statin vs statin therapy. Journal of clinical lipidology. 13(6). 997–1007.e8. 7 indexed citations
2.
Tóth, Peter P., Harold Bays, W. Virgil Brown, et al.. (2015). CHOLESTEROL IN REMNANT-LIPOPROTEINS AS MEASURED BY DIFFERENT. Journal of the American College of Cardiology. 65(10). A1569–A1569. 2 indexed citations
3.
Davidson, Michael H., Joanne E. Tomassini, Erin Jensen, et al.. (2015). Time-related trends in variability of cIMT changes in statin trials. Data in Brief. 6. 530–541. 1 indexed citations
4.
Tóth, Peter P., Alberico L. Catapano, Michel Farnier, et al.. (2015). EZETIMIBE DOES NOT INCREASE FASTING GLUCOSE LEVELS MORE THAN STATINS ALONE IN NON-DIABETIC, HYPERCHOLESTEROLEMIC PATIENTS. Journal of the American College of Cardiology. 65(10). A1633–A1633. 3 indexed citations
5.
Davidson, Michael H., Joanne E. Tomassini, Erin Jensen, et al.. (2015). Changing characteristics of statin-related cIMT trials from 1988 to 2006. Atherosclerosis. 246. 121–129. 4 indexed citations
6.
Ambegaonkar, Baishali, Diane Tipping, Adam B. Polis, Joanne E. Tomassini, & Andrew M. Tershakovec. (2014). Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis. Atherosclerosis. 237(2). 829–837. 36 indexed citations
7.
8.
Lipsky, Benjamin A., et al.. (2009). The value of a wound score for diabetic foot infections in predicting treatment outcome: A prospective analysis from the SIDESTEP trial. Wound Repair and Regeneration. 17(5). 671–677. 37 indexed citations
9.
10.
Guyton, John R., B. Greg Brown, Sergio Fazio, et al.. (2008). Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Coadministered With Extended-Release Niacin in Patients With Type IIa or Type IIb Hyperlipidemia. Journal of the American College of Cardiology. 51(16). 1564–1572. 67 indexed citations
11.
Lipsky, Benjamin A., Peter Sheehan, David G. Armstrong, et al.. (2007). Clinical predictors of treatment failure for diabetic foot infections: data from a prospective trial. International Wound Journal. 4(1). 30–38. 56 indexed citations
12.
Weaver, Arthur L., Ronald P. Messner, William W. Storms, et al.. (2006). Treatment of Patients With Osteoarthritis With Rofecoxib Compared With Nabumetone. JCR Journal of Clinical Rheumatology. 12(1). 17–25. 16 indexed citations
13.
Smugar, Steven S., Thomas J. Schnitzer, Arthur L. Weaver, et al.. (2006). Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies. Current Medical Research and Opinion. 22(7). 1353–1367. 14 indexed citations
14.
Desjardins, Paul J., Donald R. Mehlisch, David J. Chang, et al.. (2005). The Time to Onset and Overall Analgesic Efficacy of Rofecoxib 50 mg. Clinical Journal of Pain. 21(3). 241–250. 13 indexed citations
15.
Kivitz, Alan, Maria Greenwald, Stanley Cohen, et al.. (2004). Efficacy and Safety of Rofecoxib 12.5 mg Versus Nabumetone 1,000 mg in Patients with Osteoarthritis of the Knee: A Randomized Controlled Trial. Journal of the American Geriatrics Society. 52(5). 666–674. 27 indexed citations
16.
Battisti, Wendy P., Nathaniel P. Katz, Arthur L. Weaver, et al.. (2004). Pain management in osteoarthritis: A focus on onset of efficacy—a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials. Journal of Pain. 5(9). 511–520. 29 indexed citations
17.
18.
Stewart, William C., et al.. (2002). Tolerability and Efficacy of Dorzolamide Versus Acetazolamide added to Timolol. Journal of Ocular Pharmacology and Therapeutics. 18(3). 211–220. 12 indexed citations
19.
Geba, Gregory P., Arthur L. Weaver, Adam B. Polis, et al.. (2002). Efficacy of Rofecoxib, Celecoxib, and Acetaminophen in Osteoarthritis of the Knee. JAMA. 287(1). 64–64. 187 indexed citations
20.
Sharpe, Elizabeth, et al.. (1998). Comparison of the efficacy and safety of 2% dorzolamide and 0.5% betaxolol in the treatment of elevated intraocular pressure. Clinical Therapeutics. 20(3). 454–466. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel R. Morales Breakdown of academic impact, for papers by Rita Schinnar Breakdown of academic impact, for papers by Brian P. Smith Breakdown of academic impact, for papers by Julie Parkes Breakdown of academic impact, for papers by Dena Rosen Ramey Breakdown of academic impact, for papers by John Reckless Breakdown of academic impact, for papers by Frank Andersohn Breakdown of academic impact, for papers by W W Yeo Breakdown of academic impact, for papers by Concetta Rafaniello Breakdown of academic impact, for papers by R. Lassalle
Rankless by CCL
2026